Bristow L J, Hutson P H, Kulagowski J J, Leeson P D, Matheson S, Murray F, Rathbone D, Saywell K L, Thorn L, Watt A P, Tricklebank M D
Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, United Kingdom.
J Pharmacol Exp Ther. 1996 Nov;279(2):492-501.
The anticonvulsant and behavioral profile of the glycine/N-methyl-D-aspartate receptor antagonist L-701,324 [7-chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(H)quinolone] has been examined in rodents. In mice, L-701,324 protected against seizures induced by N-methyl-DL-aspartate (ED50 = 3,4 mg/kg i.v.), pentylenetetrazol (ED50 = 2.8 mg/kg i.v.) and electroshock (ED50 = 1.4 mg/kg i.v.) but was most potent against audiogenic seizures in DBA/2 mice (ED50 = 0.96 mg/kg i.p.). L-701,324 was also active p.o. in mice (ED50 = 1.9,6.7, 20.7 and 34 mg/kg against audiogenic, electroshock-induced, N-methyl-DL-aspartate-induced and pentylenetetrazol-induced seizures, respectively) but showed weaker anticonvulsant activity in rats (ED50 = 90.5 mg/kg p.o., compared with 2.3 mg/kg i.v., against pentylenetetrazol-induced seizures), most probably because of the lower brain concentrations achieved in this species. Although anticonvulsant activity was also associated with impaired rotarod performance, L-701,324 failed to significantly increase locomotor activity or dopamine turnover in the nucleus accumbens at doses of up to 10 mg/kg i.v. in mice. Thus, in contrast to N-methyl-D-aspartate receptor ion channel blockers such as MK-801 (dizocilpine), L-701,324 is a potent, p.o. active anticonvulsant with a reduced propensity to activate mesolimbic dopaminergic systems in rodents.
已在啮齿动物中研究了甘氨酸/N-甲基-D-天冬氨酸受体拮抗剂L-701,324[7-氯-4-羟基-3-(3-苯氧基)苯基-2(H)-喹诺酮]的抗惊厥和行为特征。在小鼠中,L-701,324可预防由N-甲基-DL-天冬氨酸(静脉注射半数有效量=3.4毫克/千克)、戊四氮(静脉注射半数有效量=2.8毫克/千克)和电休克(静脉注射半数有效量=1.4毫克/千克)诱导的癫痫发作,但对DBA/2小鼠的听源性癫痫发作最为有效(腹腔注射半数有效量=0.96毫克/千克)。L-701,324口服给药在小鼠中也有活性(分别对听源性、电休克诱导、N-甲基-DL-天冬氨酸诱导和戊四氮诱导的癫痫发作的半数有效量为1.9、6.7、20.7和34毫克/千克),但在大鼠中显示出较弱的抗惊厥活性(口服半数有效量=90.5毫克/千克,与静脉注射2.3毫克/千克相比,针对戊四氮诱导的癫痫发作),很可能是因为该物种大脑中达到的浓度较低。尽管抗惊厥活性也与旋转棒性能受损有关,但在小鼠中静脉注射剂量高达10毫克/千克时,L-701,324未能显著增加运动活性或伏隔核中的多巴胺周转率。因此,与N-甲基-D-天冬氨酸受体离子通道阻滞剂如MK-801(地佐环平)相比,L-701,324是一种有效的口服活性抗惊厥药,在啮齿动物中激活中脑边缘多巴胺能系统的倾向较低。